This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Implied Volatility Surging for Anthera Pharmaceuticals (ANTH) Stock Options
by Zacks Equity Research
Surging implied volatility makes Anthera Pharmaceuticals (ANTH) stock lucrative to the option traders.
Shire (SHPG) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Shire (SHPG) will report its Q4 results on Feb 14, 2018.
Will Ocaliva Sales Dampen Intercept's (ICPT) Q4 Earnings?
by Zacks Equity Research
The recent weakness in lead drug Ocaliva sales due to safety issues may mar Intercept's (ICPT) performance in the fourth quarter.
Zoetis (ZTS) Warming Up to Q4 Earnings: What's in Store?
by Zacks Equity Research
Zoetis (ZTS) is working on returning value to shareholders in the form of share buybacks and dividends.
Spectrum Pharma's Rolontis Positive in Pivotal Cancer Study
by Zacks Equity Research
Spectrum Pharmaceuticals' (SPPI) Rolontis meets primary endpoint in a phase III study for management of neutropenia in early stage breast cancer.
Will Regeneron (REGN) Disappoint Investors in Q4 Earnings?
by Zacks Equity Research
With a mixed track record, we expect investor focus on Regeneron's (REGN) Eylea sales and uptake of Dupixent when it reports Q4 results.
Keryx (KERX) Warming Up to Q4 Earnings: What's in Store?
by Zacks Equity Research
Keryx (KERX) will provide updates on lead drug Auryxia when it reports Q4 results on Feb 7.
Is a Beat in Store for Alexion (ALXN) This Earnings Season?
by Zacks Equity Research
Alexion's (ALXN) Q4 results are likely to driven by Soliris' performance.
Will Gilead (GILD) Disappoint Investors in Q4 Earnings?
by Zacks Equity Research
Biotech bigwig Gilead Sciences (GILD) Q4 results are expected to be adversely impacted by the decline in HCV market share.
Will Bristol-Myers' (BMY) Q4 Earnings Exceed Expectations?
by Zacks Equity Research
Bristol-Myers' (BMY) Opdivo is likely to play an instrumental role in driving fourth-quarter 2017 results.
What's in the Cards for GW Pharma (GWPH) in Q1 Earnings?
by Zacks Equity Research
GW Pharma (GWPH) will report fiscal first-quarter results next week. Investors focus is expected to be on the Epidiolex commercialization plan.
What's in Store for Cardinal Health (CAH) in Q2 Earnings?
by Zacks Equity Research
Pricing pressure in generics portfolio is likely to mar Cardinal Health's (CAH) top line in Q2.
Can Molecular Diagnostics Arm Up Hologic (HOLX) Q1 Earnings?
by Zacks Equity Research
Molecular Diagnostics unit's stellar performance in the first quarter of 2018 is likely to drive Hologic (HOLX) in Q1.
Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) will report its Q4 results on Jan 31, 2018.
Will Higher System Sales Drive Cerner's (CERN) Q4 Earnings?
by Zacks Equity Research
Cerner (CERN) expects solid Q4 revenues on a surge in bookings. Stiff competition remains a concern.
The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ
Anthera's Sollpura Strong on Positive Futility in Phase III
by Zacks Equity Research
Anthera (ANTH) posts positive results from the second interim futility analysis of Sollpura for EPI. Top-line data from the study is expected in the first quarter of 2018.
Anthera's Blisibimod Positive in Phase II Extension Study
by Zacks Equity Research
Anthera's (ANTH) blisibimod passes test in an extended phase II study to prove efficacy for IgA nephropathy treatment. The study also shows a trend toward preservation of renal function.
Axovant Sciences (AXON) Shows Strength: Stock Jumps 9.2%
by Debasmita Banerjee
Axovant Sciences Ltd. (AXON) shares rose a little above 9% in the last trading session.
ANTH's (ANTH) Blisibimod Completes Dosing in Phase III Study
by Zacks Equity Research
Anthera Pharmaceuticals, Inc. (ANTH) recently announced the completion of dosing in a phase II study, BRIGHT-SC. The study evaluated key pipeline candidate blisibimod for treatment of patients with IgA nephropathy (IgAN).
Should You Get Rid of Aimmune Therapeutics (AIMT) Now?
by Zacks Equity Research
Aimmune Therapeutics (AIMT) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.
BioTelemetry (BEAT) Shows Strength: Stock Moves 8.8% Higher
by Zacks Equity Research
BioTelemetry, Inc. (BEAT) shares rose almost 9% in the last trading session.
Cellect Biotechnology (APOP) Jumps: Stock Moves 10.5% Higher
by Zacks Equity Research
Cellect Biotechnology Ltd. (APOP) shares rose over 10% in the last trading session.
Bill Ackman Apologizes for Valeant Investment Error
by Zacks Equity Research
In a letter addressed to shareholders, Bill Ackman, chairman of Perishing Square Holdings, Ltd stated that investing in Valeant Pharmaceuticals (VRX) was a big mistake on his part.
Cara Therapeutics (CARA) Shows Strength: Stock Up 5.2%
by Zacks Equity Research
Cara Therapeutics, Inc. (CARA) shares rose above 5% in the last trading session.